Understanding the two faces of the COVID-19 immune response to predict clinical course and define strategies for early and late phase intervention
- Funded by Netherlands Organisation for Health Research and Development (ZonMW)
- Total publications:0 publications
Grant number: 1.043E+13
Grant search
Key facts
Disease
COVID-19Start & end year
20202024Funder
Netherlands Organisation for Health Research and Development (ZonMW)Principal Investigator
dr S. NierkensResearch Location
N/ALead Research Institution
Universitair Medisch Centrum UtrechtResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Disease models
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The immune system plays a striking dual role in COVID-19. An effective immune response ensures that the virus is attacked and cleared, but if this does not work properly, hyper-activation of the immune system appears to occur, which can lead to serious problems. It is unclear what exactly goes wrong in the immune system in patients with a serious course and how they can best be treated. The use of immune-suppressing medications is one possible strategy. Research and expected outcomes In this study, a collaboration between the UMCU, RIVM and VUmc, a model is developed of the underlying immune response in different phases of COVID by measuring functional cellular defense and circulating protein profiles of patients of different ages and with a variation in disease severity. -19. In addition, predictive biomarkers will be identified and validated that provide insight into optimal timing for specific treatments.